Healio - "NIH Collaboration Aims To Identify, Validate Immunotherapy Biomarkers" - Kristie L. Kahl

New York, NY
 – October 13, 2017  –– 

NIH launched the Partnership for Accelerating Cancer Therapies, a five-year public-private research collaboration. The $215 million effort is part of the national cancer moonshot initiative. The collaboration — managed by the Foundation for the National Institutes of Health and advised by the FDA — will focus on efforts to identify, develop and validate robust biomarkers to advance new immunotherapy treatments for cancer care. “The purpose is to find better ways to predict which patients may benefit from such therapies, and to design new approaches for those who don’t,” said Sacha Gnjatic, PhD, associate professor of medicine, hematology and medical oncology and associate director of the Human Immune Monitoring Center at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. “The partnership takes advantage of the large-scale funding and portfolios of drugs from the pharmaceutical industry to tap into the expertise of NCI-sponsored researchers and clinicians and solve these questions in the most scientifically robust manner.”

- Sacha Gnjatic, PhD, Associate Professor, Medicine, Hematology and Medical Oncology, Associate Director, Human Immune Monitoring Center, The Tisch Cancer Institute, The Icahn School of Medicine at Mount Sinai

Learn more

Additional coverage:

Crain’s Health Pulse (Subscription Required)

Forbes

Chron

Pharmaceutical Processing

Fierce Biotech